Merck said on Wednesday its experimental oral HIV medicine was found to be non-inferior to Gilead Sciences' top-selling drug ...
Stocktwits on MSN
Merck Says Its Two-Drug Regimen For HIV Treatment Proven Non-Inferior To Gilead’s Biktarvy In Study
The safety profile of the regimen was also found to be comparable to Biktarvy. ・Merck now intends to present findings from ...
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced topline results from the pivotal ...
The first gene-editing therapies for HIV/Aids are entering trials but the virus is proving once again that it is a master at ...
Scientists have found a breakthrough in the search for a cure for HIV, after research uncovered a development “previously thought impossible”. HIV can ‘hide’ itself in white blood cells, meaning the ...
Since the HIV epidemic began, the diagnosis of HIV has evolved from a death sentence to a chronic, but manageable condition by starting and staying on treatment. HIV treatment can help people live ...
Gilead Sciences, Inc. (NASDAQ: GILD) today announced positive topline results from the Phase 3 ARTISTRY-1 trial. The ...
There are several variants, or clades, of HIV in circulation. The most widely-circulating variant, HIV-1 Clade C, accounts ...
A recent Indian study suggests that the effectiveness of HIV antibody treatments varies depending on regional virus strains, calling for region-specific solutions.
HIV has become a more manageable condition in recent years, but a full cure remains elusive. Now, scientists have found promise in permanently eliminating the virus, thanks to a drug already approved ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback